Register Now for the AAPS National Biotechnology Conference
The AAPS National Biotechnology Conference (NBC) uncovers the latest science and trends that impact today’s research and pharmaceutical markets, specifically in the areas of biologics, biotechnology products, and advanced therapies. Join leading pharmaceutical scientists May 4-7, in Boston, MA, for sessions covering new modalities, technologies, and novel strategies in biotherapeutic development.
For more information about the meeting, below are the tracks and themes. Additionally, check out the NBC program.
Track 1: Inspiring Innovation in Formulation, Bioprocessing and Drug Delivery
This track focuses on the latest advances and challenges in formulation and delivery of biologics for newer and established modalities, including multi-specific antibodies, antibody-drug conjugate (ADCs), peptides, vaccines, nanomedicines, cell and gene therapies, and how prior knowledge along with current approaches can accelerate their development and delivery.
Theme 1: Accelerating Novel Formulation Development of Biologics for Newer and Established Modalities
Learn about the latest advances in formulation and delivery of complex biologics via novel dosage forms, lipid nanocarriers, 3D-printed systems, and targeted RNA approaches in addition to traditional modalities.
Theme 2: Bioprocessing, Characterization & Comparability for Complex Biologics
Recent advancements in bioprocessing involve using complete living cells or their components to optimize both upstream and downstream processes. This includes addressing host cell complexities, improving their expression, and ensuring the characterization and comparability of biopharmaceutical products.
Theme 3: Patient-Centric Product Design and Precision Medicine
Explore several facets of precision medicine that intersect to improve patient outcomes. Advances in patient-centric technologies and how point-of-care and diagnostic testing can increase the therapeutic effectiveness and compliance of patients, including improved drug delivery using combination devices, ultimately improving the product adherence and clinical outcomes.
Track 2: From Bench to Bedside: Bioanalysis and Translational Science
The rapid rise of newer (now beyond novel) therapeutic modalities has warranted innovative approaches and strategies to analyze these newer drug products and their respective constituents. Newer modalities, including but not limited to CAR-T cells, gene therapies, and protein-based drugs, demand innovative approaches to assess their pharmacokinetics (PK), pharmacodynamics (PD), and safety.
Theme 1: Breaking Barriers: Bioanalytical Innovation for Complex Biologics
Bioanalytical methods may not be sensitive enough to generate translatable pharmacokinetic, pharmacodynamic, and target engagement data to support clinical translation. This theme explores bioanalytical space surrounding newer modalities, with a focus on lipid nanoparticles (LNP), nanoliposomes, mRNA, siRNA, protein degraders, and gene therapeutics.
Theme 2: Managing Global Clinical Trials and Crises in Sample Logistics
Global clinical trials have expanded in scope and diversity, but managing patient samples has become increasingly complex. Regulations, such as the U.S. CLIA and the recent EU IVDR, affect clinical sample analysis, posing logistical challenges.
Theme 3: Preclinical and Clinical PK/PD, Safety Translation of Newer Modalities
Traditional vitro assays often have limited predictive abilities for newer modalities, and the bioanalysis of these newer modalities is often complex and multilayered, with challenging sample storage and preparation.
